BofA analyst Alec Stranahan raised the firm’s price target on MeiraGTx (MGTX) to $16 from $14 and keeps a Buy rating on the shares. The FDA’s Breakthrough Therapy Designation for AAV2-hAQP1 in Grade 2/3 radiation-induced xerostomia is “meaningful regulatory derisking for one of the company’s most important late-stage assets,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGTX:
- MeiraGTx Highlights Breakthrough Gene Therapy and Strategic Alliances
- MeiraGTx announces FDA breakthrough therapy designation for AAV2-hAQP1
- MGTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Controversial Prasad leaving FDA, NYT reports
- MeiraGTx and ZipBio sign exclusive license agreement for geographic atrophy